Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

BACKGROUND: The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2− mBC) resistance to anti-estrogen treatments. Based on results of the BOLERO-2 trial, the mTORC1 inhibitor everolimus in combination with the steroidal aromatase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Vernieri, Claudio, Corti, Francesca, Nichetti, Federico, Ligorio, Francesca, Manglaviti, Sara, Zattarin, Emma, Rea, Carmen G., Capri, Giuseppe, Bianchi, Giulia V., de Braud, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137211/
https://www.ncbi.nlm.nih.gov/pubmed/32252811
http://dx.doi.org/10.1186/s13058-020-01271-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137211/
https://www.ncbi.nlm.nih.gov/pubmed/32252811
http://dx.doi.org/10.1186/s13058-020-01271-0

Ejemplares similares